OncoSec reports data from Phase II for ImmunoPulse IL-12 and Keytruda combo

OncoSec Medical Inc. (NASDAQ:ONCS) reported data from the Phase II OMS I-102 trial in 22 melanoma patients predicted to

Read the full 193 word article

User Sign In